
Avadel Pharmaceuticals plc AVDL
€ 18.22
-0.05%
Quartalsbericht 2025-Q3
hinzugefügt 04.11.2025
Avadel Pharmaceuticals plc Zahlungsmittel 2011-2025 | AVDL
Zahlungsmittel Jährlich Avadel Pharmaceuticals plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.4 M | 31.2 M | 74 M | 50.7 M | 71.7 M | 9.77 M | 9.32 M | 16.6 M | 39.2 M | 65.1 M | 39.8 M | 6.64 M | 2.74 M | 3.46 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 74 M | 2.74 M | 33.7 M |
Zahlungsmittel Vierteljährlich Avadel Pharmaceuticals plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.8 M | 63.4 M | 56.4 M | 51.4 M | 28.6 M | 28.8 M | 35.8 M | 31.2 M | 51.8 M | 50 M | 83.4 M | 74 M | 60.7 M | 54.1 M | 60.9 M | 50.7 M | 58.2 M | 67.1 M | 59.2 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 9.77 M | 9.77 M | 9.77 M | 9.77 M | 9.32 M | 9.32 M | 9.32 M | 9.32 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 65.1 M | 65.1 M | 65.1 M | 65.1 M | 39.8 M | 24 M | 54.1 M | 55.5 M | 6.64 M | 7.8 M | 8.34 M | 14 M | 2.74 M | 3.12 M | 4.76 M | 4.35 M | 3.46 M | - | 11.6 M | 5.83 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 83.4 M | 2.74 M | 36.9 M |
Zahlungsmittel anderer Aktien in der Arzneimittelhersteller
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
114 M | $ 1.7 | 50.0 % | $ 183 M | ||
|
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | ||
|
Assertio Holdings
ASRT
|
73.4 M | $ 0.77 | -1.79 % | $ 54.7 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8.86 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
138 M | $ 5.36 | 17.8 % | $ 86.3 M | ||
|
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 11.46 | -2.22 % | $ 587 M | ||
|
Evoke Pharma
EVOK
|
4.74 M | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
87 M | $ 6.99 | 1.09 % | $ 433 M | ||
|
Harrow Health
HROW
|
74.1 M | $ 47.18 | -7.67 % | $ 1.54 B | ||
|
China Pharma Holdings
CPHI
|
600 K | $ 1.67 | 11.33 % | $ 29.2 M | ||
|
cbdMD
YCBD
|
2.45 M | $ 1.18 | 87.31 % | $ 5.09 M | ||
|
Bausch Health Companies
BHC
|
947 M | $ 6.95 | -0.93 % | $ 2.54 B | ||
|
OrganiGram Holdings
OGI
|
24.6 M | $ 1.88 | 14.72 % | $ 402 M | ||
|
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 2.61 | 4.99 % | $ 36.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
148 M | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
136 M | $ 4.83 | 1.15 % | $ 636 M | ||
|
Pacira BioSciences
PCRX
|
277 M | $ 26.28 | 2.14 % | $ 1.22 B | ||
|
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
4.09 M | $ 4.12 | -1.67 % | $ 124 M | ||
|
Jupiter Wellness
JUPW
|
349 K | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
559 M | $ 13.13 | -2.23 % | $ 1.8 B | ||
|
ProPhase Labs
PRPH
|
9.11 M | $ 0.12 | -15.26 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
8.98 M | $ 0.93 | -2.37 % | $ 21.7 M | ||
|
Sundial Growers
SNDL
|
218 M | $ 2.19 | 24.01 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
34 M | $ 0.64 | -0.02 % | $ 30.6 M | ||
|
Solid Biosciences
SLDB
|
80.2 M | $ 5.85 | -0.34 % | $ 239 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 3.59 | -3.37 % | $ 4.46 M | ||
|
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
207 M | $ 11.86 | 40.68 % | $ 7.33 B | ||
|
TherapeuticsMD
TXMD
|
4.33 M | $ 1.79 | -2.72 % | $ 18.7 M | ||
|
Zomedica Corp.
ZOM
|
13 M | - | -0.21 % | $ 98 M | ||
|
Veru
VERU
|
24.9 M | $ 2.45 | -4.3 % | $ 330 M | ||
|
Viatris
VTRS
|
1.26 B | $ 11.63 | 0.3 % | $ 14.1 B |